Mainz Biomed B.v. Stock
Price
Target price
€0.82
€0.82
2.220%
0.018
2.220%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Mainz Biomed B.v. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Mainz Biomed B.v.
sharewise wants to provide you with the best news and tools for Mainz Biomed B.v., so we directly link to the best financial data sources.
Financials
News
EQS-News: Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQS-News: Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results
EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results
EQS-News: Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
EQS-News: Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
EQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
EQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
EQS-News: Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
EQS-News: Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
EQS-News: Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
EQS-News: Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
EQS-News: Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
EQS-News: Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
EQS-News: MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
EQS-News: MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
EQS-News: Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
EQS-News: Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023
EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023
EQS-News: Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
EQS-News: Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
EQS-News: Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
EQS-News: Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
EQS-News: Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
EQS-News: Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
EQS-News: Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
EQS-News: Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
EQS-News: Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
EQS-News: Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
EQS-News: Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
EQS-News: Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
EQS-News: Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
EQS-News: Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
EQS-News: Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
EQS-News: Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
EQS-News: Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
EQS-News: Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
EQS-News: Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
EQS-News: Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA